01—Abstract
Summary
Summary of the 10-Q filed August 27, 2024. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc reported a strong quarter, with net sales increasing by 3% year-over-year to $7.9 billiona for the three months ended July 26, 2024.
This growth was driven by solid performance across key segments, including Cardiovascular and Diabetes. Diluted earnings per share (EPS) saw a significant increase to $0.80b from $0.59 in the prior year period, reflecting improved profitability. The company generated robust operating cash flow of $986 million, underscoring its strong operational execution.
Medtronic also continued to return capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value. The company's financial position remains strong, with ample liquidity to fund operations and strategic initiatives.
02—Key points
Key Highlights
- Net sales grew 3% to $7.9 billion, driven by growth in key segments like Cardiovascular and Diabetes.
- Diluted earnings per share (EPS) increased to $0.80 from $0.59 in the prior year's comparable period.
- Operating cash flow improved to $986 million from $875 million year-over-year.
- The company repurchased approximately $2.5 billion in shares during the quarter, signaling confidence and commitment to returning value to shareholders.
- The Cardiovascular segment showed a 6% increase in net sales, bolstered by strong performance in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic.
- The Diabetes segment reported a 12% increase in net sales, primarily due to the strong adoption of the MiniMed 780G insulin pump system in the U.S.
- Medtronic maintained a strong liquidity position with $1.3 billion in cash and cash equivalents and $6.5 billion in current investments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Medtronic plc kept $0.13.
- Revenue$7.92B100.0%
- Cost of revenue−$2.76B34.9%
- Gross profit$5.15B65.1%
- Operating costs−$3.88B49.0%
- Operating income$1.28B16.1%
- Interest, other & tax−$229.0M2.9%
- Net income$1.05B13.3%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed August 27, 2024Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $7.92B$7.70B | +2.8% |
| Cost of Revenue | $2.76B$2.63B | +5.1% |
| Gross Profit | $5.15B$5.07B | +1.6% |
| SG&A Expenses | $2.65B$2.61B | +1.6% |
| Operating Income | $1.28B$1.27B | +0.8% |
| Net Income | $1.05B$797.00M | +31.6% |
| EPS (Basic) | $0.81$0.59 | +37.3% |
| EPS (Diluted) | $0.80$0.59 | +35.6% |
| Shares Outstanding (Basic) | 1.29B1.33B | −2.8% |
| Shares Outstanding (Diluted) | 1.30B1.33B | −2.8% |
05—Questions
Frequently Asked Questions
What was Medtronic's revenue performance in the latest quarter?
Medtronic reported net sales of $7.9 billion for the three months ended July 26, 2024, representing a 3% increase compared to the same period in the prior year. This growth was primarily driven by solid performance in its Cardiovascular and Diabetes segments.
How did Medtronic's profitability change compared to the previous year?
Profitability improved significantly, with diluted earnings per share (EPS) increasing to $0.80 from $0.59 in the comparable prior year period. This reflects an effective translation of sales growth into bottom-line results.
What is Medtronic's cash flow generation like?
The company demonstrated strong cash flow generation, with net cash provided by operating activities totaling $986 million for the quarter, an increase from $875 million in the prior year's comparable period. Free cash flow was $466 million.
How is Medtronic managing its capital and returning value to shareholders?
Medtronic continues to focus on capital allocation, with significant share repurchases during the quarter totaling approximately $2.5 billion. The company also consistently pays dividends, demonstrating a commitment to returning value to its shareholders.
06—Continue